Skip to main content
. 2018 Jan 12;91(1084):20170705. doi: 10.1259/bjr.20170705

Table 1.

Patients’ characteristics regarding tumour grade. a and b, same letter denotes the lack of statistically significant difference between groups.

Grade 1 (n = 7) Grade 2 (n = 29) Grade 3 (n = 34) p
Age, mean ± SD 46.14 ± 6.26 51.38 ± 13.32 44.04 ± 12.93 0.134
Type, n (%)
 IDC 4 (9.3) 15 (34.9) 24 (55.8) 0.271
 ILC 1 (16.7) 4 (66.7) 1 (16.7)
 Other 2 (28.6) 2 (28.6) 3 (42.9)
 ADC-B 500 (×10−3), median (min–max) 1.190 (0.108–1.630) 1.020 (0.155–1.410) 0.979 (0.108–1.630) 0.485
 Ki-67 (%), median (min–max) 5.00 (2.00–20.00)a 6.00 (2.00–70.00)a 40.00 (5.00–95.00)b <0.001**
 ER (%), median (min–max) 90.00 (0.00–100.00) 90.00 (20.00–100.00) 75.00 (0.00–100.00) 0.077
 PR (%), median (min–max) 90.00 (0.00–90.00) 90.00 (0.00–100.00) 70.00 (0.00–100.00) 0.263
C-erb-B2, n (%)
 0 7 (21.2) 13 (39.4) 13 (39.4) 0.003*
 1 0 (0.0) 7 (77.8) 2 (22.2)
 2 0 (0.0) 0 (0.0) 3 (100.0)
 3 0 (0.0) 1 (9.1) 10 (90.9)
Lymphovascular Invasion, n (%)
 Negative 6 (16.2) 15 (40.5) 16 (43.2) 0.291
 Positive 1 (5.3) 6 (31.6) 12 (63.2)
Neoadjuvant Chemotherapy, n (%)
 Absent 6 (11.3) 19 (35.8) 28 (52.8) 0.182
 Present 1 (33.3) 2 (66.7) 0 (0.0)

Same letter (a, b, c, * and **) denotes the lack of statistically significant difference between groups. ADC, apparent diffusion coefficient; ER, estrogen receptore; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; PR, progesteron receptore; SD, standard deviation.